Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL

被引:70
|
作者
Mekori, YA
Gilfillan, AM
Akin, C
Hartmann, K
Metcalfe, DD
机构
[1] Meir Hosp, Dept Med, Kefar Sava, Israel
[2] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
[3] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA
关键词
apoptosis; Bcl-2; Bcl-X; c-kit; mast cell;
D O I
10.1023/A:1011083031272
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It is well established that human mast cell proliferation and maturation are regulated by kit ligand (stem cell factor). Little is known, however, about how these two processes are negatively regulated and thus, how mast cell number is controlled in normal and pathologic conditions. We therefore first hypothesized that SCF-dependent human mast cells would undergo programmed cell death (apoptosis) on removal of SCF as has been shown for growth factor-dependent rodent mast cells. We then examined whether SCF acts as a survival factor through the regulation of the bcl-2 family of apoptosis-regulatory genes. As hypothesized, elimination of SCF from primary peripheral blood-derived human mast cell cultures resulted in a significant apoptotic process. During apoptosis, down-regulation of the two apoptosis-regulatory proteins Bcl-2 and Bcl-X-L was observed. Moreover, a deregulated expression of these two proteins was found in two human mast cell lines which are SCF-independent. Thus, SCF functions as a survival factor by repressing apoptosis of human mast cells through Bcl-2 and Bcl-X-L. Deregulated expression of these antiapoptotic proteins may contribute to proliferation and accumulation of mast cells in certain forms of systemic mast cell disorders.
引用
收藏
页码:171 / 174
页数:4
相关论文
共 50 条
  • [21] Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment
    Hopkins-Donaldson, S
    Cathomas, R
    Simoes-Wüst, AP
    Kurtz, S
    Belyanskya, L
    Stahel, RA
    Zangemeister-Wittke, U
    INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (02) : 160 - 166
  • [22] Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck
    Pena, JC
    Thompson, CB
    Recant, W
    Vokes, EE
    Rudin, CM
    CANCER, 1999, 85 (01) : 164 - 170
  • [24] BCL-2 AND BCL-XL: POTENTIAL TARGETS FOR INHIBITION BY siRNA
    Yakobson, E.
    Vestin, A.
    Weinstein, J.
    Sergeyev, V.
    Mandel, M.
    Khazanov, E.
    Barenholz, Y.
    Agami, R.
    Bank, I.
    Sidi, Y.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3634 - 3634
  • [25] Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
    Westhoff, Mike-Andrew
    Schuler-Ortoli, Marie
    Zerrinius, Daniela
    Hadzalic, Amina
    Schuster, Andrea
    Strobel, Hannah
    Scheuerle, Angelika
    Wong, Tiana
    Wirtz, Christian Rainer
    Debatin, Klaus-Michael
    Peraud, Aurelia
    PHARMACEUTICALS, 2022, 15 (01)
  • [26] Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL
    Daver, Naval
    Konopleva, Marina
    BLOOD, 2016, 128 (10) : 1316 - 1317
  • [27] Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma
    U. Leiter
    R. M. Schmid
    P. Kaskel
    R. U. Peter
    G. Krähn
    Archives of Dermatological Research, 2000, 292 : 225 - 232
  • [28] Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma
    Leiter, U
    Schmid, RM
    Kaskel, P
    Peter, RU
    Krähn, G
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2000, 292 (05) : 225 - 232
  • [29] A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor
    Aguilar, Angelo
    Zhou, Haibin
    Chen, Jianfang
    Liu, Liu
    Bai, Longchuan
    McEachern, Donna
    Yang, Chao-Yie
    Meagher, Jennifer
    Stuckey, Jeanne
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (07) : 3048 - 3067
  • [30] EXPRESSION OF BCL-2 AND BCL-XL IN BREAST-CANCER
    CARROLL, AG
    LIPPMAN, ME
    MOLECULAR BIOLOGY OF THE CELL, 1995, 6 : 1439 - 1439